Supplementary Appendix: Efficacy and Safety of the Oral Janus Kinase 1 Inhibitor Povorcitinib in Patients With Extensive Vitiligo in a Phase 2, Randomized, Double-Blinded, Dose-Ranging, Placebo-Controlled Study
Published: 9 June 2025| Version 1 | DOI: 10.17632/52jtsjjd24.1
Contributor:
Wendy van der SpuyDescription
Supplementary Appendix for Efficacy and Safety of the Oral Janus Kinase 1 Inhibitor Povorcitinib in Patients With Extensive Vitiligo in a Phase 2, Randomized, Double-Blinded, Dose-Ranging, Placebo-Controlled Study
Files
Categories
Clinical Trial, Safety, Vitiligo, Efficacy Study
Funding
Incyte (United States)